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Chronic heart failure (CHF) is common, and more than half 
of patients diagnosed with CHF will die within 5 years.1,2 
Medical advances, particularly beta blocker therapy 
and implantable cardiac defibrillators,3 mean that many 
individuals with CHF are living longer and cared for in the 
community. Patients with CHF experience a wide range 
of frequently distressing symptoms and in addition to 
breathlessness, pain, nausea and constipation, low mood is 
common and generally poorly controlled.1,4–6 The symptom 
burden is of similar severity to patients with cancer,7 
therefore integrating supportive care into CHF treatment is 
important in both primary and secondary care settings.
specific palliative care services, although originally cancer based, now 
also address the needs of individuals with nonmalignant conditions. the 
terms ‘palliative’ and ‘supportive’ care are often used interchangeably: 
both strive to improve the quality of life of patients who have serious 
or life threatening disease and to provide support for family members. 
Generally, this is best viewed as an approach to care rather than a 
discrete phase or setting of care. 
 the evidence base to guide the palliative and supportive aspects of 
care are less explicit than curative management3 and further research 
is required. high rates of comorbidity, particularly renal and hepatic 
dysfunction, alter the potential risk-benefit profile of pharmacotherapy.3
Palliative care and CHF patients
heart failure is a diverse and heterogeneous syndrome and patients will 
have variable disease trajectories and needs requiring tailored, targeted 
management.
 Palliative and supportive strategies can add to the complexity of 
treatment. Palliative care can be challenging in primary care, particularly 
when after hours care is required. supportive treatments, such as 
introducing opioid therapy for dyspnoea,8 require close monitoring 
and titration. therefore it is recommended that patients be referred 
to community based, interdisciplinary heart failure programs.these 
programs aim to promote self management in the community, optimise 






Chronic heart failure is common, particularly in older 
individuals, and comorbidities are frequent. Patients with 
end stage heart failure can be highly symptomatic and 
require careful monitoring and treatment adjustment to 
improve symptoms.
Objective
This article summarises the fundamentals of implementing 
palliative care in general practice and provides guidelines on 
caring for chronic heart failure patients at the end of life.
Discussion
The high mortality in chronic heart failure underscores 
the importance of effective communication, symptom 
management and advanced care planning. The 
unpredictability and uncertainty around the timing of death 
mean that individuals, and their families, may be less likely 
to have an understanding of their prognosis or have access 
to supportive and palliative care. Ideally, patients with 
symptomatic chronic heart failure should be managed in 
collaboration with a multidisciplinary heart failure program. 
Symptom management can be achieved by additive 
therapies and access to specialist palliative care services 
should be considered when the symptom burden is high. 
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unnecessary admissions to hospital. Accessibility can be challenging, 
particularly for rural and remote patients, although there is an increasing 
focus on telemedicine strategies to decrease health inequities. the use of 
case conferencing item numbers may also facilitate communication across 
care settings, which is particularly useful in end of life care.9
Which CHF patients benefit?
determining the end stage of disease can be difficult – typically functional 
decline and end organ damage signal that life is potentially limited. 
complete assessment (including cardiology review) is required to ensure 
that reversible causes have been excluded, and treatment adherence 
(both patient and provider) considered before concluding a patient has end 
stage disease.10
 end of life care discussions are important for all patients, however the 
following criteria are associated with poor prognosis, therefore palliative 













arrest without an implantable cardiac defibrillator
•	 Unexplained	weight	loss	of	≥5	kg	over	past	6	months	(excluding	index	
admission diuresis).11,12
Effective communication and treatment goals 
Perhaps the most important issue in addressing supportive care needs 
is ensuring the patient, family and health professionals are aware of the 
goals of treatment. Although health professionals dread this ‘difficult 
conversation’, in which treatment options and the likelihood of death 
are discussed, data suggests patients and their families welcome the 
opportunity for transparent and open discussion.13 ensuring all treatment 
providers are ‘on the same page’ is important to avoid ambiguity in 
treatment goals and futile, unwanted treatments. 
 communication across healthcare teams, particularly primary and 
secondary care teams, is vital. documenting patient preferences for 
the level and place of care at the end of life is important. complex, 
difficult and value laden decisions, such as withdrawing and withholding 
treatment, should not be made as the patient is being placed in the 
back of the ambulance. Patients and their families should also be 
reassured that withholding specific treatments, such as cardiopulmonary 
resuscitation or ceasing certain medications, does not mean the end 
of all active care. in fact, often the patient and their family’s needs are 
increased at the end of life. Table 1 provides an example of how to 
approach this conversation. General practitioners are well placed to have 
these conversations as they understand their patients’ conditions and 
social situation, which are both pivotal to assisting patients with chF in 
advance care planning. 
The importance of symptom 
management
the efficacy of supportive and palliative care is largely assessed by 
the quality of symptom management and the reduction of distress for 
patients and their family. it is important to remember that medications 
such as beta blockades, angiotensin converting enzyme inhibitors (Aceis), 
angiotensin ii inhibitors, and spironolactone improve symptoms in chF.3 
therefore these medications should not be withdrawn without careful 
consideration, even when it is clear that the patient is end stage. in 
some instances, hypotension, worsening renal function and electrolyte 
imbalance may require downward titration of medications. Generally, 
minimising the diuretic dose prevents hypotension and other chF 
Table 1. Approach for discussing prognosis and 
advanced care planning 
•	 If there is suspicion of clinical depression, psychiatric 
evaluation and treatment is necessary before 
formulation of advanced care directives
•	 Choose a time and setting conducive to discussion
•	 Encourage participation of family members and/or 
caregivers
•	 Where possible involve all treating teams and primary 
care clinicians
•	 Assess the level of involvement that the patient wants 
in clinical decision making
•	 Assess the understanding of the patient concerning 
diagnosis and treatment
•	 Declare professional recommendations and empirical 
risks and benefits of treatments where available, eg. 
‘It appears that your kidney function is getting worse 
and therefore the risk that you will develop further 
complications is increasing’
•	 Introduce joint decision making processes and 
language, eg. ‘We are going to work together’
•	 Use language which acknowledges patient autonomy, 
eg. ‘We would like your opinion’
•	 Invite questions and comments and ask questions to 
ascertain understanding
•	 Be perceptive to body language reflecting withdrawal 
and/or distress 
•	 Acknowledge the uncertainty of the prognosis
•	 Provide the option for delaying decisions, eg. ‘You can 
tell us your decision at your next visit’
•	 Allow opportunity to discuss decisions with family 
and caregivers
•	 Offer ongoing decision support and contact details to 
clarify information
•	 Where possible follow up in the next few days to 
ascertain level of comfort with conversation.
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medications can be continued.14
 the principles of symptom control are the same irrespective of the 
patient’s diagnosis. A clinical assessment is vital, including the patient’s 
adherence to treatment recommendations and potentially reversible causes 
of decompensation, such as infection, anaemia or ischaemia. Table 2 
provides guidelines for undertaking a clinical assessment in end of life care. 
Breathlessness
breathlessness is a common and distressing symptom in chF and a highly 
subjective sensation.14 therapy needs to improve the patient’s subjective 
sensation rather than simply correct abnormal physiological parameters.15 
When evidence of fluid overload is present, increased doses of diuretics are 
warranted. diuretic titration is an important part of care and the addition 
of thiazide diuretics to loop diuretics may overcome diuretic resistance.16,17 
intravenous administration may be more effective than oral administration if 
diuretic resistance is probable and congestion is problematic. 
 breathlessness is not always associated with fluid overload but can be 
attributed to other causes such as anaemia, fatigue and deconditioning.18 
opioids have an important role in managing breathlessness in the 
palliative phase of illness.19,20 evidence supporting the use of oxygen in 
mildly hypoxaemic patients is sparse.21 benzodiazepines can be used to 
relieve the anxiety associated with breathlessness. information regarding 
dosing can be accessed through the recently revised therapeutic 
Guidelines: Palliative care.22 As a general principle, start at low doses, 
observe responses, and slowly uptitrate. opioids should be titrated to 
the level of symptoms and can be used without causing respiratory 
depression or excessive drowsiness.23 constipation should be anticipated 
and instructions regarding aperients should be provided.
 in addition to pharmacological strategies, a range of 
nonpharmacological approaches can be useful and can also increase 
the sense of control for patients, and their families. Advice on posture, 
relaxation techniques and having a flow of air across the face, from 
a fan or an open window, is important. Airflow is believed to relieve 
breathlessness through inhibitory fibres from facial receptors.24 
 sleep disordered breathing is common in chF and should be 
assessed and managed appropriately.25 the majority of people with 
sleep disordered breathing have central sleep apnoea and the minority, 
obstructive sleep apnoea.26 the use of continuous positive airway 
pressure can provide symptomatic relief and improve breathlessness and 
fatigue.27 
 Given the difficulties in accessing polysomnography in Australia,28 
if sleep disordered breathing is considered a cause of symptoms, sleep 
evaluation needs to occur earlier in the illness trajectory rather then in the 
later stages of chF. 
Gastrointestinal symptoms
Gastrointestinal symptoms, such as nausea or vomiting, constipation 
and incontinence are important in the palliative phase of chF. Anti-
emetics can be prescribed to relieve nausea. constipation is common 
and aperients may be required, particularly if opioids are prescribed.29 
Anorexia is frequently a concern for family members, but is part of the 






Bowel and bladder function – 
continence and constipation
Oedema – consider presence of sacral 
edema due to immobility




Capacity to self care††















Cultural Cultural significance of death and 
dying






Religious beliefs and desires for 
burials
*   The World Health Organization Three Step Analgesic 
Ladder approach is useful in assessment and 
management of pain and/or discomfort36
**   A visual analogue scale is a valid and reliable 
strategy to monitor levels of dyspnoea37
†   Consider using anchors or reference points such as 
walking to the bathroom to determine deterioration 
in functional status
† †  Where possible it is useful to use validated measures 
for patient reported outcomes such as depression, 
anxiety, stress, functional status, oedema, pain and 
quality of life. This not only facilitates empirical 
clinical decision making but also communication 
across healthcare sectors
#   Sequential measurements of psychometric measures 
over time can be useful in monitoring prognosis and 
functional status35
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aging partner, engaging social services is a high priority. cultural beliefs 
are also an important consideration in approaching end of life care.41 
Family members should be provided with bereavement care and referred 
to services where appropriate.
Complementary and alternative therapies
complementary and alternative therapies, such as relaxation, biofeedback 
and stress management, may relieve symptoms such as breathlessness 
and anxiety.42 there is an increased trend in the use of complementary 
therapies in the community17 and this may increase with deteriorating 
health, as people strive for alternative solutions. creating an open 
environment encourages disclosure and may prevent adverse interactions. 
For example, some alternate therapies can potentiate the effects of 
warfarin and digoxin.43
Withdrawing and withholding treatments
Withdrawing and withholding treatments is perhaps one of the 
most challenging decisions faced by health professionals. effective 
communication and appraisal of prognosis is important. Guidelines 
for turning off implantable cardiac defibrillators are available and can 
assist in clinical decision making.44 the decision to deactivate should 
be undertaken in consultation with the patient, their family members 
and, where possible, a cardiologist. in special circumstances, industry 
representatives can be enlisted to visit the patient’s home or hospice to 
assist in deactivation. 
 the decision to withdraw or withhold medication should be based on 
a comprehensive clinical assessment, including the capacity to swallow. 
Generally, the aim should to be maintain core chF drugs, such as beta 
blockers, for as long as possible as they assist in decreasing symptom 
burden.3 if a treatment goal is to reduce the number of tablets taken by 
the	patient,	then	withdrawing/withholding	medications,	such	as	digoxin	
and cholesterol lowering drugs, should be considered. Warfarin therapy 
should be critically assessed in terms of risk and benefits. diagnostic tests 
should be avoided unless there is a clear intent to act upon the results, 
particularly in the last weeks of life.11
Conclusion
A palliative care approach is relevant across the chF trajectory, not only 
for those expected to die within days or weeks, although it is particularly 
relevant for those with end stage disease. Palliative care should be 
integrated as part of a team approach. At the end of life, symptom burden 
is the focus of care. General practitioners and primary care professionals 
play a crucial role in assisting patients and family to navigate this 
challenging and vulnerable phase. engaging specialist heart failure 
and palliative care services may be appropriate when symptom burden 
remains high and is refractory to conventional methods.
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end of life trajectory in many conditions, including chF.30 cachexia 
should be managed with an unrestricted calorie intake and dietary 
supplements where appropriate.31 small frequent meals may be better 
tolerated. Reduced dietary intake may necessitate warfarin adjustment 
as the international normalised ratio (inR) can rise when anorexia and 
catabolism is present.32 
Elimination
strategies to manage incontinence should be implemented to promote 
patient comfort and avoid pressure areas and ulcers. urinary incontinence 
may be managed by changing the timing of diuretic doses, or by the use of 
a urinary catheter, incontinence pads or noninvasive continence devices.
Fatigue
Fatigue is common in chF and the causes can be both physiological and 
psychological.33 both emotional and cognitive dimensions influence 
fatigue perception and energy conservation techniques are useful. 
exercise is an important therapeutic strategy and prescription of both 
active and passive exercise, even in end stage disease, is important.1 this 
also minimises dependent oedema and breathlessness and decreases 
the risk of decubitus ulcers and other complications related to immobility. 
Psychostimulants have been shown to decrease fatigue in cancer,34 
although there is no data on chF. Anaemia is common in chF and is an 
important source of fatigue and exercise intolerance. erythropoietin and 
iron supplementation are promising for treating anaemia but are still 
largely experimental.35 
Uraemia
in the palliative phase of chF, progressive renal impairment is common 
and a marker of poor outcome.36,37 Renal dysfunction may be due 
to vascular changes, congestion and medication effects. nausea 
associated with uraemia can be treated with haloperidol or another 
anti-emetics.14 skin irritation due to uraemia may respond to topical 
steroids and agitated delirium may be treated with neuroleptic agents.38 
morphine metabolite accumulation occurs in patients with severe renal 
impairment, resulting in clinical features of neuroexcitation such as 
agitated delirium and frequent myoclonus.39 
Pain
many studies identify pain as a symptom in chF. the causes of this pain 
are unclear but can include musculoskeletal problems.40 management of 
pain should follow evidence based treatment strategies and it is important 
for clinicians to recognise that pain can be a problem.
The importance of cultural, 
psychological, social and spiritual care
depression is a frequent comorbidity in chF and should be screened for 
and treated appropriately. At the end of life, relationships and spiritual 
and existential care are of great importance. social workers, volunteer 
organisations and pastoral care should be engaged where appropriate. 
Given that many individuals with chF are elderly and live alone or with an 
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